Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec

Rheumatology

Volumn 42, Issue SUPPL. 3, 2003, Pages

  Moride, Yola ^a,b   Ducruet, T ^a   Rochon, S ^c   Lavoie, F ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PFIZER INC   (United States)

Author keywords

Adherence; COX 2 specific inhibitors; Drug utilization; Non specific NSAIDs; Persistency

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANADA; DATA BASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; QUEBEC; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES; SURVIVAL RATE; TIME FACTORS;

EID: 0242693498     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rooney PJ, Capell HA, Paterson S, Buchanan WW, Dick WC. Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacy. Br J Clin Pharmacol 1978;5:453-5.
2. Capell H, Rennie J, Rooney P et al. Patient compliance: a novel method for testing non-steroidal antiinflammatory analgesics in rheumatoid arthritis. J Rheumatol 1979;6:584-93.
3. Walker AM, Chan K-WA, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95.
4. Langman M, Kahler KH, Kong SX et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001;10:517-24.
5. Leufkens HG, Ameling CB, Hekster YA, Bakker A. Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population. Pharm Weekbl Sci 1990;12:97-103.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
8. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10: 290-6.
9. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530-7.
10. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
11. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62.
12. Chan KW, Walker AM, Yood RA. An equilibrium model of drug utilization. J Clin Epidemiol 1993;46: 113-21.